Max Kelsen, an Australian company is utilizing artificial intelligence (AI) to help foresee the benefits of cancer treatments. The organization is putting together whole genome sequencing and artificial intelligence into the clinical practice and the research of cancer.
Therkelsen-terry said, “The key to predicting patient treatment outcomes lies in finding and interpreting the patterns and genes and significance in the genomes of patients who have responded best to previous treatments. There’s a range of genomic sequencing from panels that look at a few select genes like 23andMe and ancestry.com, through to broader exome analysis, through to whole genome, and we started with a point of view that we want to look at the entire genome.”
One out of every four Australians end up getting diagnosed with cancer and though immunotherapy has shown promising results in the improvement patient survival among various types of cancer, including lung cancer and melanoma it isn’t a sure shot to be of the same effect for all the patients.